The impact of HIV is delayed: Gilead introduced the effectiveness of the drug to stop HIV an infection – July 17, 2024

The blind section of the examine of a brand new drug to stop HIV an infection has been accomplished. Open trials will proceed, however registration is predicted as early as 2025. On June 17, social networks are actively posting information concerning the affect on HIV with the assistance of a brand new vaccine – the injectable drug Lenacapavir from Gilead. In fact, it can’t be vaccinated. Sadly, additionally an impact over HIV. Alexey Lakhov, a marketing consultant to the charity group Humanitarian Motion, informed Fontanka about this.

Gilead right this moment introduced outcomes from an interim evaluation of its pivotal Part 3 trial of twice-yearly Lenacapavir. It has been confirmed to be 100% efficient in stopping HIV infections in girls in Uganda and South Africa. As Alexey Lakhov defined, research are additionally being carried out in Argentina, Brazil, Mexico, Peru, South Africa, Thailand and the USA amongst males who’ve intercourse with males, transgender girls and non-binary folks. Anticipated outcomes: early 2025. In the USA, analysis continues to be evaluating the security and suitability of the drug for ladies and individuals who inject medication.

“This isn’t a vaccine, however a product of pre-exposure prophylaxis supposed for individuals who are susceptible to buying the immune virus,” says Alexey Lakhov. – Bear in mind, post-exposure prophylaxis (intercourse with an contaminated particular person, contact with the blood of an contaminated particular person) that enables an individual to not get HIV an infection whether it is used inside 72 hours after the an infection? And this can be a drug that’s given to stop a placed on the illness even earlier than the provider of the virus is contacted. It’s administered as soon as each six months constantly till the danger of harmful contact disappears amongst males who’ve intercourse with males and individuals who use medication. The examine can also be performed amongst African girls, as a result of the virus is widespread there, and males, due to their mentality, don’t use of condoms”.

First, Lenacapavir was created for antiretroviral therapy of sufferers with mutated and drug-resistant ART. However it was additionally discovered to have the power to stop HIV an infection for a sure time frame.

In keeping with Alexei Lakhov, the drug could also be registered in 2025. Within the US, the fee is $42,250 for the primary yr of therapy and $39,000 for every subsequent yr.